Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9UPS8
UPID:
ANR26_HUMAN
Alternative names:
-
Alternative UPACC:
Q9UPS8; A6NH29; Q2TAZ3; Q6ZR14; Q9H1Q1; Q9NSK9; Q9NTD5; Q9NW69
Background:
Ankyrin repeat domain-containing protein 26 plays a pivotal role in adipogenesis and feeding behavior regulation. Its unique structure, characterized by the ankyrin repeat, enables it to participate in crucial cellular processes.
Therapeutic significance:
Linked to Thrombocytopenia 2, a disorder marked by reduced platelet count leading to bleeding and clotting issues, this protein's genetic variants offer a direct pathway to understanding and potentially treating this condition.